3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to be myocarditis from about 44.2 million doses of Comirnaty (Pfizer) and 115 reports which have been assessed as likely to be myocarditis from about 5.4 million doses of Spikevax (Moderna).
To 30 October 2022, we have received about 4,290 reports from approximately 3.7 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) in 12-17 year olds. The most commonly reported reactions are chest pain, headache, dizziness, nausea and fever.